Solid Biosciences
SLDB
39 hedge funds and large institutions have $74.8M invested in Solid Biosciences in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 6 closing their positions.
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
11% more funds holding
Funds holding: 35 → 39 (+4)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
12% less capital invested
Capital invested by funds: $85.3M → $74.8M (-$10.6M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $7K
122.44% less ownership
Funds ownership: 203.04% → 80.6% (-122%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FC
Finepoint Capital
Boston,
Massachusetts
|
+$1.62M |
| 2 |
PVI
Pura Vida Investments
New York
|
+$1.35M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$1.26M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$640K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$112K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$1.84M |
| 2 |
CCM
CAAS Capital Management
New York
|
-$235K |
| 3 |
Renaissance Technologies
New York
|
-$78.1K |
| 4 |
Millennium Management
New York
|
-$69K |
| 5 |
OWP
Old Well Partners
Charlotte,
North Carolina
|
-$58.1K |
SLDB Hedge Fund Activity: Q1 2023 in Review
39 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Solid Biosciences (SLDB) for Q1 2023, worth a combined $74.8M — down 12% from $85.3M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new SLDB positions and 6 closed out — a net gain of 4 holders — while 8 added to existing stakes and 9 trimmed.
The largest buyer was Finepoint Capital, adding an estimated $1.62M. The largest seller was K2 Principal Fund, exiting entirely with an estimated $1.84M sold.
- 39 institutional investors held Solid Biosciences (SLDB) as of Q1 2023, up from 35 in Q4 2022.
- Funds reported $74.8M of Solid Biosciences stock for Q1 2023, down 12% quarter-over-quarter.
- 10 funds opened new Solid Biosciences positions in Q1 2023 and 6 closed out, a net change of +4 holders.
- The largest Solid Biosciences buyer in Q1 2023 was Finepoint Capital, an estimated $1.62M added.
- The largest Solid Biosciences seller in Q1 2023 was K2 Principal Fund, an estimated $1.84M sold.
Based on aggregated 13F filings for Q1 2023.